Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1

We set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in ErbB2-positive breast and lung cancers. A cell-based in vitro site-directed mutagenesis lapatinib resistance model identified several mutations, including the gatekeeper ErbB...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangyuan, Wang, Xiaoqi, Hibshoosh, Hanina, Jin, Cheng, Halmos, Balazs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169529/
https://www.ncbi.nlm.nih.gov/pubmed/25238247
http://dx.doi.org/10.1371/journal.pone.0106349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169529/
https://www.ncbi.nlm.nih.gov/pubmed/25238247
http://dx.doi.org/10.1371/journal.pone.0106349

Ejemplares similares